These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
297 related articles for article (PubMed ID: 32231295)
1. A randomized proof-of-mechanism trial applying the 'fast-fail' approach to evaluating κ-opioid antagonism as a treatment for anhedonia. Krystal AD; Pizzagalli DA; Smoski M; Mathew SJ; Nurnberger J; Lisanby SH; Iosifescu D; Murrough JW; Yang H; Weiner RD; Calabrese JR; Sanacora G; Hermes G; Keefe RSE; Song A; Goodman W; Szabo ST; Whitton AE; Gao K; Potter WZ Nat Med; 2020 May; 26(5):760-768. PubMed ID: 32231295 [TBL] [Abstract][Full Text] [Related]
2. Selective kappa-opioid antagonism ameliorates anhedonic behavior: evidence from the Fast-fail Trial in Mood and Anxiety Spectrum Disorders (FAST-MAS). Pizzagalli DA; Smoski M; Ang YS; Whitton AE; Sanacora G; Mathew SJ; Nurnberger J; Lisanby SH; Iosifescu DV; Murrough JW; Yang H; Weiner RD; Calabrese JR; Goodman W; Potter WZ; Krystal AD Neuropsychopharmacology; 2020 Sep; 45(10):1656-1663. PubMed ID: 32544925 [TBL] [Abstract][Full Text] [Related]
3. Double-blind, placebo-controlled, proof-of-concept trial of a kappa-selective opioid receptor antagonist augmentation in treatment-resistant depression. Fava M; Mazzone E; Freeman M; Flynn M; Judge H; Hoeppner B; Hock RS; Shui A; Macaluso M; Morrison MF; Carpenter LL; Shelton R; Zajecka J; Papakostas GI Ann Clin Psychiatry; 2020 Feb; 32(4):18-26. PubMed ID: 33125454 [TBL] [Abstract][Full Text] [Related]
4. The kappa opioid receptor antagonist aticaprant reverses behavioral effects from unpredictable chronic mild stress in male mice. Jacobson ML; Wulf HA; Browne CA; Lucki I Psychopharmacology (Berl); 2020 Dec; 237(12):3715-3728. PubMed ID: 32894343 [TBL] [Abstract][Full Text] [Related]
5. Aticaprant, a kappa opioid receptor antagonist, and the recovered 'interest and pleasure' in the concept of major depressive disorder. Demyttenaere K Eur Arch Psychiatry Clin Neurosci; 2024 Jul; ():. PubMed ID: 38969753 [TBL] [Abstract][Full Text] [Related]
6. LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders. Rorick-Kehn LM; Witkin JM; Statnick MA; Eberle EL; McKinzie JH; Kahl SD; Forster BM; Wong CJ; Li X; Crile RS; Shaw DB; Sahr AE; Adams BL; Quimby SJ; Diaz N; Jimenez A; Pedregal C; Mitch CH; Knopp KL; Anderson WH; Cramer JW; McKinzie DL Neuropharmacology; 2014 Feb; 77():131-44. PubMed ID: 24071566 [TBL] [Abstract][Full Text] [Related]
7. A randomized, double-blind, placebo-controlled study of the kappa opioid receptor antagonist, CERC-501, in a human laboratory model of smoking behavior. Jones JD; Babalonis S; Marcus R; Vince B; Kelsh D; Lofwall MR; Fraser H; Paterson B; Martinez S; Martinez DM; Nunes EV; Walsh SL; Comer SD Addict Biol; 2020 Jul; 25(4):e12799. PubMed ID: 31240842 [TBL] [Abstract][Full Text] [Related]